REBECCA GROCHOWSKI: Open Payments
NPI 1861046567 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$508 in 21 payments from 11 companies in 2025. Trend: 2023 $1,219 · 2024 $938 · 2025 $508
Food & beverage: $508
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 3 | $98 |
| GlaxoSmithKline, LLC. | 3 | $67 |
| Genentech USA, Inc. | 3 | $66 |
| Merck Sharp & Dohme LLC | 2 | $53 |
| AstraZeneca Pharmaceuticals LP | 3 | $51 |
| E.R. Squibb & Sons, L.L.C. | 2 | $49 |
| Novartis Pharmaceuticals Corporation | 1 | $46 |
| Gilead Sciences, Inc. | 1 | $24 |
| Stemline Therapeutics Inc. | 1 | $21 |
| PFIZER INC. | 1 | $18 |
Products named: TECVAYLI, KEYTRUDA, KISQALI, RYBREVANT, OPDIVO, Itovebi, OJJAARA, Trodelvy.
Industry payments across MD — which companies pay providers there.
